Gilead's Single-Tablet "Quad" Regimen For HIV Achieves A High Rate Of Virologic Suppr
Gilead Sciences, Inc. (Nasdaq:GILD) announced Phase II clinical trial results showing that its investigational fixed-dose single-tablet "Quad" regimen of elvitegravir, GS 9350 (cobicistat) and Truvada(R) (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection exhibited antiretroviral activity comparable to thatofAtripla(R) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg)...
More...
Gilead Sciences, Inc. (Nasdaq:GILD) announced Phase II clinical trial results showing that its investigational fixed-dose single-tablet "Quad" regimen of elvitegravir, GS 9350 (cobicistat) and Truvada(R) (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection exhibited antiretroviral activity comparable to thatofAtripla(R) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg)...
More...